Home World News EMA Recommends Extension of Indications for Serplulimab World News EMA Recommends Extension of Indications for Serplulimab By Ogkologos - April 22, 2026 342 0 Facebook Twitter Google+ Pinterest WhatsApp New indications concern the treatment of patients with oesophageal squamous cell carcinoma and non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole... September 24, 2021 New on NCI’s Websites for November 2021 November 5, 2021 Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... March 26, 2024 Immune Responses Similar for Adjuvanted and Standard Dose Influenza Vaccines for... February 4, 2025 Load more HOT NEWS Activity of Alectinib for ALK-Rearranged Metastatic Solid Tumours, Other Than NSCLC EMA Recommends Granting a Conditional Marketing Authorisation for Pemigatinib Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms Deputy Spends His Days Off Teaching Life Skills To Young Boys...
